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ABSTRACT
Background: Rheumatoid arthritis is a chronic inflammatory disease with an increased 
risk of diabetes and insulin resistance. Aims: To determine the prevalence o f undiagnosed 
dysglycaemia and investigate the factors associated with it in patients with established RA. 
Methods: This was a cross-sectional study conducted in a rheumatology centre. One 
hundred fifty five consecutive patients were recruited. The inclusion criteria were patients 
with established RA, age > 30 years. Patients with diabetes or pre-diabetes were excluded. 
Demographic details, clinical data on RA and anthropometric measurements were obtained. 
Laboratory investigations performed included erythrocyte sedimentation rate, C-reactive 
protein, intracellular adhesion molecule (ICAM), lipid profile and plasma glucose. A 75g- 
oral glucose tolerance test was performed to determine dysglycaemia. Comparison of 
variables were done between two groups; dysglycaemia and normoglycaemia.
Results: The mean age o f patients was 57.2±8.1 years and majority (87.7%) were female. 
35.5% (n=155) had dysglycaemia. Apart from ever smoker, there were no significant 
differences observed in age, gender and disease duration between the groups. Although RA 
disease activity and the average dose o f corticosteroid used within six months were higher 
in dysglycaemia group, the differences were not statistically significant. Significant 
differences were observed in waist circumferences, weight, systolic and diastolic blood 
pressure, high-density lipoprotein, triglycerides and ICAM levels but after multivariate 
analysis, the predictors o f dysglycaemia were ever smoker and high triglyceride level. 
Conclusion: One-third of our patients had dysglycaemia and they were heavier, larger 
waist circumference, higher blood pressure and LDL-c, and lower HDL-c. Predictors of 
dysglycaemia in established RA aged >30 years were ever smoker (OR 4.28) and high 
triglyceride level (OR 3.29).
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CHAPTER ONE 
INTRODUCTION
1.1 RESEARCH BACKGROUND
Rheumatoid arthritis (RA) is a chronic progressive inflammatory autoimmune 
disease, mainly affecting the joints. The clinical symptoms of the disease varied from mild 
self-limited disease to severe joint destruction and physical disability (Plenge, 2009). Apart 
from increased in morbidity due to physical disability, RA patients have been shown to 
have more than twice mortality rates compared to the general population (Gonzalez et al., 
2007). Cardiovascular disease (CVD) is a significant cause o f mortality in patients with 
RA (Wolfe et al., 1994) and in a population-based cohort study, the incidence o f CVD in 
patients with RA is at least equal to that observed for type 2 DM (T2DM) (Rho et al., 2009). 
The cause o f the excess cardiovascular risk in patients with RA is multifactorial; apart from 
ongoing high-grade inflammation (Rho et al., 2009), T2DM has also been shown to 
contribute to the cause o f increased cardiovascular risks (Choy, Ganeshalingam, Semb, 
Szekanecz, & Nurmohamed, 2014; Kitas & Gabriel, 2011).
Several studies have shown that patients with RA have higher risks of diabetes and 
insulin resistance (IR) (Solomon, Love, Canning, & Schneeweiss, 2010; Su, Chen, Young 
& Lian, 2013; Ursini et al., 2016). The elevated risk o f developing diabetes in RA was 
initially thought to be due to the chronic use o f corticosteroid (Caldwell & Furst, 1991). 
However recent study proposed that development of T2DM in RA is irrespective of 
glucocorticoids use (Solomon et al., 2010). The ongoing inflammation in RA, evidenced 
by elevated C-reactive protein (CRP), interleukin-6 (IL-6) and tumour necrosis factor-a 
(TNF-a) have been shown to be associated with the development o f diabetes (Goldberg, 
2009; Wang et al., 2013). These inflammatory markers are often raised in patients with RA 
especially during active disease and are commonly elevated many years before the clinical 
manifestation o f RA (Steenbergen, Huizinga, & Helm-van Mil, 2013).
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